Global RNA Interference (RNAi) Drug Delivery Market Research Report 2021

Publisher Name :
Date: 11-Jan-2021
No. of pages: 123
Inquire Before Buying

The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type

- Nanoparticle Drug Delivery Technology

- Pulmonary Drug Delivery Technology

- Nucleic Acid Drug Delivery Technology

- Aptamer Drug Delivery Technology

Segment by Application

- Infectious Diseases

- Cardiology

- Oncology

- Neurology

- Ophthalmology

- Metabolic Disorders

By Region

- North America

- - U.S.

- - Canada

- Europe

- - Germany

- - France

- - U.K.

- - Italy

- - Russia

- Asia-Pacific

- - China

- - Japan

- - South Korea

- - India

- - Australia

- - Taiwan

- - Indonesia

- - Thailand

- - Malaysia

- - Philippines

- - Vietnam

- Latin America

- - Mexico

- - Brazil

- - Argentina

- Middle East & Africa

- - Turkey

- - Saudi Arabia

- - U.A.E

By Company

- Metabolic disorders

- Alnylam Pharmaceuticals Inc

- Merck & Co. Inc

- Access Pharmaceuticals Inc

- Dicerna Pharmaceuticals Inc

- Calondo Pharmaceuticals Inc

- Marina Biotech Inc

- RXi Pharmaceuticals Corp

- Quark Pharmaceuticals Inc

- Silence Therapeutics plc

- Tacere Therapeutics Inc

- PhaseRx Inc

- Sirnaomics Inc

- Traversa Therapeutics Inc

Global RNA Interference (RNAi) Drug Delivery Market Research Report 2021

Table of Contents
1 RNA Interference (RNAi) Drug Delivery Market Overview
1.1 Product Overview and Scope of RNA Interference (RNAi) Drug Delivery
1.2 RNA Interference (RNAi) Drug Delivery Segment by Type
1.2.1 Global RNA Interference (RNAi) Drug Delivery Sales Growth Rate Comparison by Type (2021-2027)
1.2.2 Nanoparticle Drug Delivery Technology
1.2.3 Pulmonary Drug Delivery Technology
1.2.4 Nucleic Acid Drug Delivery Technology
1.2.5 Aptamer Drug Delivery Technology
1.3 RNA Interference (RNAi) Drug Delivery Segment by Application
1.3.1 RNA Interference (RNAi) Drug Delivery Sales Comparison by Application: (2021-2027)
1.3.2 Infectious Diseases
1.3.3 Cardiology
1.3.4 Oncology
1.3.5 Neurology
1.3.6 Ophthalmology
1.3.7 Metabolic Disorders
1.4 Global RNA Interference (RNAi) Drug Delivery Market Size Estimates and Forecasts
1.4.1 Global RNA Interference (RNAi) Drug Delivery Revenue 2016-2027
1.4.2 Global RNA Interference (RNAi) Drug Delivery Sales 2016-2027
1.4.3 RNA Interference (RNAi) Drug Delivery Market Size by Region: 2016 Versus 2021 Versus 2027
2 RNA Interference (RNAi) Drug Delivery Market Competition by Manufacturers
2.1 Global RNA Interference (RNAi) Drug Delivery Sales Market Share by Manufacturers (2016-2021)
2.2 Global RNA Interference (RNAi) Drug Delivery Revenue Market Share by Manufacturers (2016-2021)
2.3 Global RNA Interference (RNAi) Drug Delivery Average Price by Manufacturers (2016-2021)
2.4 Manufacturers RNA Interference (RNAi) Drug Delivery Manufacturing Sites, Area Served, Product Type
2.5 RNA Interference (RNAi) Drug Delivery Market Competitive Situation and Trends
2.5.1 RNA Interference (RNAi) Drug Delivery Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest RNA Interference (RNAi) Drug Delivery Players Market Share by Revenue
2.5.3 Global RNA Interference (RNAi) Drug Delivery Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 RNA Interference (RNAi) Drug Delivery Retrospective Market Scenario by Region
3.1 Global RNA Interference (RNAi) Drug Delivery Retrospective Market Scenario in Revenue by Region: 2016-2021
3.2 Global RNA Interference (RNAi) Drug Delivery Retrospective Market Scenario in Sales by Region: 2016-2021
3.3 North America RNA Interference (RNAi) Drug Delivery Market Facts & Figures by Country
3.3.1 North America RNA Interference (RNAi) Drug Delivery Sales by Country
3.3.2 North America RNA Interference (RNAi) Drug Delivery Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe RNA Interference (RNAi) Drug Delivery Market Facts & Figures by Country
3.4.1 Europe RNA Interference (RNAi) Drug Delivery Sales by Country
3.4.2 Europe RNA Interference (RNAi) Drug Delivery Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific RNA Interference (RNAi) Drug Delivery Market Facts & Figures by Region
3.5.1 Asia Pacific RNA Interference (RNAi) Drug Delivery Sales by Region
3.5.2 Asia Pacific RNA Interference (RNAi) Drug Delivery Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America RNA Interference (RNAi) Drug Delivery Market Facts & Figures by Country
3.6.1 Latin America RNA Interference (RNAi) Drug Delivery Sales by Country
3.6.2 Latin America RNA Interference (RNAi) Drug Delivery Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa RNA Interference (RNAi) Drug Delivery Market Facts & Figures by Country
3.7.1 Middle East and Africa RNA Interference (RNAi) Drug Delivery Sales by Country
3.7.2 Middle East and Africa RNA Interference (RNAi) Drug Delivery Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global RNA Interference (RNAi) Drug Delivery Historic Market Analysis by Type
4.1 Global RNA Interference (RNAi) Drug Delivery Sales Market Share by Type (2016-2021)
4.2 Global RNA Interference (RNAi) Drug Delivery Revenue Market Share by Type (2016-2021)
4.3 Global RNA Interference (RNAi) Drug Delivery Price by Type (2016-2021)
5 Global RNA Interference (RNAi) Drug Delivery Historic Market Analysis by Application
5.1 Global RNA Interference (RNAi) Drug Delivery Sales Market Share by Application (2016-2021)
5.2 Global RNA Interference (RNAi) Drug Delivery Revenue Market Share by Application (2016-2021)
5.3 Global RNA Interference (RNAi) Drug Delivery Price by Application (2016-2021)
6 Key Companies Profiled
6.1 Metabolic disorders
6.1.1 Metabolic disorders Corporation Information
6.1.2 Metabolic disorders Description and Business Overview
6.1.3 Metabolic disorders RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2016-2021)
6.1.4 Metabolic disorders Product Portfolio
6.1.5 Metabolic disorders Recent Developments/Updates
6.2 Alnylam Pharmaceuticals Inc
6.2.1 Alnylam Pharmaceuticals Inc Corporation Information
6.2.2 Alnylam Pharmaceuticals Inc Description and Business Overview
6.2.3 Alnylam Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2016-2021)
6.2.4 Alnylam Pharmaceuticals Inc Product Portfolio
6.2.5 Alnylam Pharmaceuticals Inc Recent Developments/Updates
6.3 Merck & Co. Inc
6.3.1 Merck & Co. Inc Corporation Information
6.3.2 Merck & Co. Inc Description and Business Overview
6.3.3 Merck & Co. Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2016-2021)
6.3.4 Merck & Co. Inc Product Portfolio
6.3.5 Merck & Co. Inc Recent Developments/Updates
6.4 Access Pharmaceuticals Inc
6.4.1 Access Pharmaceuticals Inc Corporation Information
6.4.2 Access Pharmaceuticals Inc Description and Business Overview
6.4.3 Access Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Access Pharmaceuticals Inc Product Portfolio
6.4.5 Access Pharmaceuticals Inc Recent Developments/Updates
6.5 Dicerna Pharmaceuticals Inc
6.5.1 Dicerna Pharmaceuticals Inc Corporation Information
6.5.2 Dicerna Pharmaceuticals Inc Description and Business Overview
6.5.3 Dicerna Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2016-2021)
6.5.4 Dicerna Pharmaceuticals Inc Product Portfolio
6.5.5 Dicerna Pharmaceuticals Inc Recent Developments/Updates
6.6 Calondo Pharmaceuticals Inc
6.6.1 Calondo Pharmaceuticals Inc Corporation Information
6.6.2 Calondo Pharmaceuticals Inc Description and Business Overview
6.6.3 Calondo Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2016-2021)
6.6.4 Calondo Pharmaceuticals Inc Product Portfolio
6.6.5 Calondo Pharmaceuticals Inc Recent Developments/Updates
6.7 Marina Biotech Inc
6.6.1 Marina Biotech Inc Corporation Information
6.6.2 Marina Biotech Inc Description and Business Overview
6.6.3 Marina Biotech Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Marina Biotech Inc Product Portfolio
6.7.5 Marina Biotech Inc Recent Developments/Updates
6.8 RXi Pharmaceuticals Corp
6.8.1 RXi Pharmaceuticals Corp Corporation Information
6.8.2 RXi Pharmaceuticals Corp Description and Business Overview
6.8.3 RXi Pharmaceuticals Corp RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2016-2021)
6.8.4 RXi Pharmaceuticals Corp Product Portfolio
6.8.5 RXi Pharmaceuticals Corp Recent Developments/Updates
6.9 Quark Pharmaceuticals Inc
6.9.1 Quark Pharmaceuticals Inc Corporation Information
6.9.2 Quark Pharmaceuticals Inc Description and Business Overview
6.9.3 Quark Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2016-2021)
6.9.4 Quark Pharmaceuticals Inc Product Portfolio
6.9.5 Quark Pharmaceuticals Inc Recent Developments/Updates
6.10 Silence Therapeutics plc
6.10.1 Silence Therapeutics plc Corporation Information
6.10.2 Silence Therapeutics plc Description and Business Overview
6.10.3 Silence Therapeutics plc RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2016-2021)
6.10.4 Silence Therapeutics plc Product Portfolio
6.10.5 Silence Therapeutics plc Recent Developments/Updates
6.11 Tacere Therapeutics Inc
6.11.1 Tacere Therapeutics Inc Corporation Information
6.11.2 Tacere Therapeutics Inc RNA Interference (RNAi) Drug Delivery Description and Business Overview
6.11.3 Tacere Therapeutics Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2016-2021)
6.11.4 Tacere Therapeutics Inc Product Portfolio
6.11.5 Tacere Therapeutics Inc Recent Developments/Updates
6.12 PhaseRx Inc
6.12.1 PhaseRx Inc Corporation Information
6.12.2 PhaseRx Inc RNA Interference (RNAi) Drug Delivery Description and Business Overview
6.12.3 PhaseRx Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2016-2021)
6.12.4 PhaseRx Inc Product Portfolio
6.12.5 PhaseRx Inc Recent Developments/Updates
6.13 Sirnaomics Inc
6.13.1 Sirnaomics Inc Corporation Information
6.13.2 Sirnaomics Inc RNA Interference (RNAi) Drug Delivery Description and Business Overview
6.13.3 Sirnaomics Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2016-2021)
6.13.4 Sirnaomics Inc Product Portfolio
6.13.5 Sirnaomics Inc Recent Developments/Updates
6.14 Traversa Therapeutics Inc
6.14.1 Traversa Therapeutics Inc Corporation Information
6.14.2 Traversa Therapeutics Inc RNA Interference (RNAi) Drug Delivery Description and Business Overview
6.14.3 Traversa Therapeutics Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2016-2021)
6.14.4 Traversa Therapeutics Inc Product Portfolio
6.14.5 Traversa Therapeutics Inc Recent Developments/Updates
7 RNA Interference (RNAi) Drug Delivery Manufacturing Cost Analysis
7.1 RNA Interference (RNAi) Drug Delivery Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of RNA Interference (RNAi) Drug Delivery
7.4 RNA Interference (RNAi) Drug Delivery Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 RNA Interference (RNAi) Drug Delivery Distributors List
8.3 RNA Interference (RNAi) Drug Delivery Customers
9 RNA Interference (RNAi) Drug Delivery Market Dynamics
9.1 RNA Interference (RNAi) Drug Delivery Industry Trends
9.2 RNA Interference (RNAi) Drug Delivery Growth Drivers
9.3 RNA Interference (RNAi) Drug Delivery Market Challenges
9.4 RNA Interference (RNAi) Drug Delivery Market Restraints
10 Global Market Forecast
10.1 RNA Interference (RNAi) Drug Delivery Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of RNA Interference (RNAi) Drug Delivery by Type (2022-2027)
10.1.2 Global Forecasted Revenue of RNA Interference (RNAi) Drug Delivery by Type (2022-2027)
10.2 RNA Interference (RNAi) Drug Delivery Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of RNA Interference (RNAi) Drug Delivery by Application (2022-2027)
10.2.2 Global Forecasted Revenue of RNA Interference (RNAi) Drug Delivery by Application (2022-2027)
10.3 RNA Interference (RNAi) Drug Delivery Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of RNA Interference (RNAi) Drug Delivery by Region (2022-2027)
10.3.2 Global Forecasted Revenue of RNA Interference (RNAi) Drug Delivery by Region (2022-2027)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Tables
Table 1. Global RNA Interference (RNAi) Drug Delivery Sales (K Units) Growth Rate Comparison by Type (2021-2027)
Table 2. Global RNA Interference (RNAi) Drug Delivery Sales (K Units) Comparison by Application (2021-2027)
Table 3. Global RNA Interference (RNAi) Drug Delivery Market Size by Region (US$ Million) (2016 VS 2021 VS 2027)
Table 4. Key Manufacturers RNA Interference (RNAi) Drug Delivery Covered in This Study
Table 5. Global RNA Interference (RNAi) Drug Delivery Sales (K Units) of Key Manufacturers (2016-2021)
Table 6. Global RNA Interference (RNAi) Drug Delivery Sales Share by Manufacturers (2016-2021)
Table 7. Global RNA Interference (RNAi) Drug Delivery Revenue (US$ Million) by Manufacturers (2016-2021)
Table 8. Global RNA Interference (RNAi) Drug Delivery Revenue Share by Manufacturers (2016-2021)
Table 9. Global Market RNA Interference (RNAi) Drug Delivery Average Price (USD/Unit) of Key Manufacturers (2016-2021)
Table 10. Manufacturers RNA Interference (RNAi) Drug Delivery Manufacturing Sites and Area Served
Table 11. Manufacturers RNA Interference (RNAi) Drug Delivery Product Type
Table 12. Global RNA Interference (RNAi) Drug Delivery Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global RNA Interference (RNAi) Drug Delivery by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in RNA Interference (RNAi) Drug Delivery as of 2020)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global RNA Interference (RNAi) Drug Delivery Sales by Region (2016-2021) & (K Units)
Table 16. Global RNA Interference (RNAi) Drug Delivery Sales Market Share by Region (2016-2021)
Table 17. Global RNA Interference (RNAi) Drug Delivery Revenue by Region (2016-2021) & (US$ Million)
Table 18. North America RNA Interference (RNAi) Drug Delivery Sales by Country (2016-2021) & (K Units)
Table 19. North America RNA Interference (RNAi) Drug Delivery Sales Market Share by Country (2016-2021)
Table 20. North America RNA Interference (RNAi) Drug Delivery Revenue by Country (2016-2021) & (US$ Million)
Table 21. North America RNA Interference (RNAi) Drug Delivery Revenue Market Share by Country (2016-2021)
Table 22. Europe RNA Interference (RNAi) Drug Delivery Sales by Country (2016-2021) & (K Units)
Table 23. Europe RNA Interference (RNAi) Drug Delivery Sales Market Share by Country (2016-2021)
Table 24. Europe RNA Interference (RNAi) Drug Delivery Revenue by Country (2016-2021) & (US$ Million)
Table 25. Europe RNA Interference (RNAi) Drug Delivery Revenue Market Share by Country (2016-2021)
Table 26. Asia Pacific RNA Interference (RNAi) Drug Delivery Sales by Region (2016-2021) & (K Units)
Table 27. Asia Pacific RNA Interference (RNAi) Drug Delivery Sales Market Share by Region (2016-2021)
Table 28. Asia Pacific RNA Interference (RNAi) Drug Delivery Revenue by Region (2016-2021) & (US$ Million)
Table 29. Asia Pacific RNA Interference (RNAi) Drug Delivery Revenue Market Share by Region (2016-2021)
Table 30. Latin America RNA Interference (RNAi) Drug Delivery Sales by Country (2016-2021) & (K Units)
Table 31. Latin America RNA Interference (RNAi) Drug Delivery Sales Market Share by Country (2016-2021)
Table 32. Latin America RNA Interference (RNAi) Drug Delivery Revenue by Country (2016-2021) & (US$ Million)
Table 33. Latin America RNA Interference (RNAi) Drug Delivery Revenue Market Share by Country (2016-2021)
Table 34. Middle East and Africa RNA Interference (RNAi) Drug Delivery Sales by Country (2016-2021) & (K Units)
Table 35. Middle East and Africa RNA Interference (RNAi) Drug Delivery Sales Market Share by Country (2016-2021)
Table 36. Middle East and Africa RNA Interference (RNAi) Drug Delivery Revenue by Country (2016-2021) & (US$ Million)
Table 37. Middle East and Africa RNA Interference (RNAi) Drug Delivery Revenue Market Share by Country (2016-2021)
Table 38. Global RNA Interference (RNAi) Drug Delivery Sales (K Units) by Type (2016-2021)
Table 39. Global RNA Interference (RNAi) Drug Delivery Sales Market Share by Type (2016-2021)
Table 40. Global RNA Interference (RNAi) Drug Delivery Revenue (Million US$) by Type (2016-2021)
Table 41. Global RNA Interference (RNAi) Drug Delivery Revenue Share by Type (2016-2021)
Table 42. Global RNA Interference (RNAi) Drug Delivery Price (USD/Unit) by Type (2016-2021)
Table 43. Global RNA Interference (RNAi) Drug Delivery Sales (K Units) by Application (2016-2021)
Table 44. Global RNA Interference (RNAi) Drug Delivery Sales Market Share by Application (2016-2021)
Table 45. Global RNA Interference (RNAi) Drug Delivery Revenue (Million US$) by Application (2016-2021)
Table 46. Global RNA Interference (RNAi) Drug Delivery Revenue Share by Application (2016-2021)
Table 47. Global RNA Interference (RNAi) Drug Delivery Price (USD/Unit) by Application (2016-2021)
Table 48. Metabolic disorders Corporation Information
Table 49. Metabolic disorders Description and Business Overview
Table 50. Metabolic disorders RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 51. Metabolic disorders RNA Interference (RNAi) Drug Delivery Product
Table 52. Metabolic disorders Recent Developments/Updates
Table 53. Alnylam Pharmaceuticals Inc Corporation Information
Table 54. Alnylam Pharmaceuticals Inc Description and Business Overview
Table 55. Alnylam Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 56. Alnylam Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Product
Table 57. Alnylam Pharmaceuticals Inc Recent Developments/Updates
Table 58. Merck & Co. Inc Corporation Information
Table 59. Merck & Co. Inc Description and Business Overview
Table 60. Merck & Co. Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 61. Merck & Co. Inc RNA Interference (RNAi) Drug Delivery Product
Table 62. Merck & Co. Inc Recent Developments/Updates
Table 63. Access Pharmaceuticals Inc Corporation Information
Table 64. Access Pharmaceuticals Inc Description and Business Overview
Table 65. Access Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 66. Access Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Product
Table 67. Access Pharmaceuticals Inc Recent Developments/Updates
Table 68. Dicerna Pharmaceuticals Inc Corporation Information
Table 69. Dicerna Pharmaceuticals Inc Description and Business Overview
Table 70. Dicerna Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 71. Dicerna Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Product
Table 72. Dicerna Pharmaceuticals Inc Recent Developments/Updates
Table 73. Calondo Pharmaceuticals Inc Corporation Information
Table 74. Calondo Pharmaceuticals Inc Description and Business Overview
Table 75. Calondo Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 76. Calondo Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Product
Table 77. Calondo Pharmaceuticals Inc Recent Developments/Updates
Table 78. Marina Biotech Inc Corporation Information
Table 79. Marina Biotech Inc Description and Business Overview
Table 80. Marina Biotech Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 81. Marina Biotech Inc RNA Interference (RNAi) Drug Delivery Product
Table 82. Marina Biotech Inc Recent Developments/Updates
Table 83. RXi Pharmaceuticals Corp Corporation Information
Table 84. RXi Pharmaceuticals Corp Description and Business Overview
Table 85. RXi Pharmaceuticals Corp RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 86. RXi Pharmaceuticals Corp RNA Interference (RNAi) Drug Delivery Product
Table 87. RXi Pharmaceuticals Corp Recent Developments/Updates
Table 88. Quark Pharmaceuticals Inc Corporation Information
Table 89. Quark Pharmaceuticals Inc Description and Business Overview
Table 90. Quark Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 91. Quark Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Product
Table 92. Quark Pharmaceuticals Inc Recent Developments/Updates
Table 93. Silence Therapeutics plc Corporation Information
Table 94. Silence Therapeutics plc Description and Business Overview
Table 95. Silence Therapeutics plc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 96. Silence Therapeutics plc RNA Interference (RNAi) Drug Delivery Product
Table 97. Silence Therapeutics plc Recent Developments/Updates
Table 98. Tacere Therapeutics Inc Corporation Information
Table 99. Tacere Therapeutics Inc Description and Business Overview
Table 100. Tacere Therapeutics Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 101. Tacere Therapeutics Inc RNA Interference (RNAi) Drug Delivery Product
Table 102. Tacere Therapeutics Inc Recent Developments/Updates
Table 103. PhaseRx Inc Corporation Information
Table 104. PhaseRx Inc Description and Business Overview
Table 105. PhaseRx Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 106. PhaseRx Inc RNA Interference (RNAi) Drug Delivery Product
Table 107. PhaseRx Inc Recent Developments/Updates
Table 108. Sirnaomics Inc Corporation Information
Table 109. Sirnaomics Inc Description and Business Overview
Table 110. Sirnaomics Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 111. Sirnaomics Inc RNA Interference (RNAi) Drug Delivery Product
Table 112. Sirnaomics Inc Recent Developments/Updates
Table 113. Traversa Therapeutics Inc Corporation Information
Table 114. Traversa Therapeutics Inc Description and Business Overview
Table 115. Traversa Therapeutics Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 116. Traversa Therapeutics Inc RNA Interference (RNAi) Drug Delivery Product
Table 117. Traversa Therapeutics Inc Recent Developments/Updates
Table 118. Production Base and Market Concentration Rate of Raw Material
Table 119. Key Suppliers of Raw Materials
Table 120. RNA Interference (RNAi) Drug Delivery Distributors List
Table 121. RNA Interference (RNAi) Drug Delivery Customers List
Table 122. RNA Interference (RNAi) Drug Delivery Market Trends
Table 123. RNA Interference (RNAi) Drug Delivery Growth Drivers
Table 124. RNA Interference (RNAi) Drug Delivery Market Restraints
Table 125. Global RNA Interference (RNAi) Drug Delivery Sales Forecast by Type (2022-2027) & (K Units)
Table 126. Global RNA Interference (RNAi) Drug Delivery Sales Market Share Forecast by Type (2022-2027)
Table 127. Global RNA Interference (RNAi) Drug Delivery Revenue Forecast by Type (2022-2027) & (US$ Million)
Table 128. Global RNA Interference (RNAi) Drug Delivery Revenue Market Share Forecast by Type (2022-2027)
Table 129. Global RNA Interference (RNAi) Drug Delivery Sales Forecast by Application (2022-2027) & (K Units)
Table 130. Global RNA Interference (RNAi) Drug Delivery Sales Market Share Forecast by Application (2022-2027)
Table 131. Global RNA Interference (RNAi) Drug Delivery Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 132. Global RNA Interference (RNAi) Drug Delivery Revenue Market Share Forecast by Application (2022-2027)
Table 133. Global RNA Interference (RNAi) Drug Delivery Sales Forecast by Region (2022-2027) & (K Units)
Table 134. Global RNA Interference (RNAi) Drug Delivery Sales Market Share Forecast by Region (2022-2027)
Table 135. Global RNA Interference (RNAi) Drug Delivery Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 136. Global RNA Interference (RNAi) Drug Delivery Revenue Market Share Forecast by Region (2022-2027)
Table 137. Research Programs/Design for This Report
Table 138. Key Data Information from Secondary Sources
Table 139. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of RNA Interference (RNAi) Drug Delivery
Figure 2. Global RNA Interference (RNAi) Drug Delivery Market Share by Type in 2020 & 2027
Figure 3. Nanoparticle Drug Delivery Technology Product Picture
Figure 4. Pulmonary Drug Delivery Technology Product Picture
Figure 5. Nucleic Acid Drug Delivery Technology Product Picture
Figure 6. Aptamer Drug Delivery Technology Product Picture
Figure 7. Global RNA Interference (RNAi) Drug Delivery Market Share by Application in 2020 & 2027
Figure 8. Infectious Diseases
Figure 9. Cardiology
Figure 10. Oncology
Figure 11. Neurology
Figure 12. Ophthalmology
Figure 13. Metabolic Disorders
Figure 14. Global RNA Interference (RNAi) Drug Delivery Revenue, (US$ Million), 2016 VS 2021 VS 2027
Figure 15. Global RNA Interference (RNAi) Drug Delivery Market Size 2016-2027 (US$ Million)
Figure 16. Global RNA Interference (RNAi) Drug Delivery Sales 2016-2027 (K Units)
Figure 17. Global RNA Interference (RNAi) Drug Delivery Market Size Market Share by Region: 2016 VS 20210 VS 2027
Figure 18. RNA Interference (RNAi) Drug Delivery Sales Share by Manufacturers in 2020
Figure 19. Global RNA Interference (RNAi) Drug Delivery Revenue Share by Manufacturers in 2020
Figure 20. The Global 5 and 10 Largest RNA Interference (RNAi) Drug Delivery Players: Market Share by Revenue in 2020
Figure 21. RNA Interference (RNAi) Drug Delivery Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021
Figure 22. Global RNA Interference (RNAi) Drug Delivery Sales Market Share by Region (2016-2021)
Figure 23. Global RNA Interference (RNAi) Drug Delivery Sales Market Share by Region in 2020
Figure 24. Global RNA Interference (RNAi) Drug Delivery Revenue Market Share by Region (2016-2021)
Figure 25. Global RNA Interference (RNAi) Drug Delivery Revenue Market Share by Region in 2020
Figure 26. U.S. RNA Interference (RNAi) Drug Delivery Revenue Growth Rate (2016-2021) (US$ Million)
Figure 27. Canada RNA Interference (RNAi) Drug Delivery Revenue Growth Rate (2016-2021) (US$ Million)
Figure 28. Germany RNA Interference (RNAi) Drug Delivery Revenue Growth Rate (2016-2021) (US$ Million)
Figure 29. France RNA Interference (RNAi) Drug Delivery Revenue Growth Rate (2016-2021) (US$ Million)
Figure 30. U.K. RNA Interference (RNAi) Drug Delivery Revenue Growth Rate (2016-2021) (US$ Million)
Figure 31. Italy RNA Interference (RNAi) Drug Delivery Revenue Growth Rate (2016-2021) (US$ Million)
Figure 32. Russia RNA Interference (RNAi) Drug Delivery Revenue Growth Rate (2016-2021) (US$ Million)
Figure 33. China RNA Interference (RNAi) Drug Delivery Revenue Growth Rate (2016-2021) (US$ Million)
Figure 34. Japan RNA Interference (RNAi) Drug Delivery Revenue Growth Rate (2016-2021) (US$ Million)
Figure 35. South Korea RNA Interference (RNAi) Drug Delivery Revenue Growth Rate (2016-2021) (US$ Million)
Figure 36. India RNA Interference (RNAi) Drug Delivery Revenue Growth Rate (2016-2021) (US$ Million)
Figure 37. Australia RNA Interference (RNAi) Drug Delivery Revenue Growth Rate (2016-2021) (US$ Million)
Figure 38. Taiwan RNA Interference (RNAi) Drug Delivery Revenue Growth Rate (2016-2021) (US$ Million)
Figure 39. Indonesia RNA Interference (RNAi) Drug Delivery Revenue Growth Rate (2016-2021) (US$ Million)
Figure 40. Thailand RNA Interference (RNAi) Drug Delivery Revenue Growth Rate (2016-2021) (US$ Million)
Figure 41. Malaysia RNA Interference (RNAi) Drug Delivery Revenue Growth Rate (2016-2021) (US$ Million)
Figure 42. Philippines RNA Interference (RNAi) Drug Delivery Revenue Growth Rate (2016-2021) (US$ Million)
Figure 43. Vietnam RNA Interference (RNAi) Drug Delivery Revenue Growth Rate (2016-2021) (US$ Million)
Figure 44. Mexico RNA Interference (RNAi) Drug Delivery Revenue Growth Rate (2016-2021) (US$ Million)
Figure 45. Brazil RNA Interference (RNAi) Drug Delivery Revenue Growth Rate (2016-2021) (US$ Million)
Figure 46. Argentina RNA Interference (RNAi) Drug Delivery Revenue Growth Rate (2016-2021) (US$ Million)
Figure 47. Turkey RNA Interference (RNAi) Drug Delivery Revenue Growth Rate (2016-2021) (US$ Million)
Figure 48. Saudi Arabia RNA Interference (RNAi) Drug Delivery Revenue Growth Rate (2016-2021) (US$ Million)
Figure 49. U.A.E RNA Interference (RNAi) Drug Delivery Revenue Growth Rate (2016-2021) (US$ Million)
Figure 50. Sales Market Share of RNA Interference (RNAi) Drug Delivery by Type (2016-2021)
Figure 51. Sales Market Share of RNA Interference (RNAi) Drug Delivery by Application (2016-2021)
Figure 52. Sales Market Share of RNA Interference (RNAi) Drug Delivery by Application in 2020
Figure 53. Revenue Share of RNA Interference (RNAi) Drug Delivery by Application (2016-2021)
Figure 54. Revenue Share of RNA Interference (RNAi) Drug Delivery by Application in 2020
Figure 55. Manufacturing Cost Structure of RNA Interference (RNAi) Drug Delivery
Figure 56. Manufacturing Process Analysis of RNA Interference (RNAi) Drug Delivery
Figure 57. RNA Interference (RNAi) Drug Delivery Industrial Chain Analysis
Figure 58. Channels of Distribution
Figure 59. Distributors Profiles
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
  • Global Gene Synthesis Service Market Growth (Status and Outlook) 2021-2026
    Published: 26-Jan-2021        Price: US 3660 Onwards        Pages: 118
    According to this latest study, the 2020 growth of Gene Synthesis Service will have significant change from previous year. By the most conservative estimates of global Gene Synthesis Service market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ 295.1 million in 2019. Over the next five years the Gene Synthesis Service market will register a 19.0% CAGR in terms of revenue, the global market size will reach US$ 591.5 million by 2025. ......
  • Global Cell Free Protein Expression Market Growth (Status and Outlook) 2021-2026
    Published: 26-Jan-2021        Price: US 3660 Onwards        Pages: 130
    According to this latest study, the 2020 growth of Cell Free Protein Expression will have significant change from previous year. By the most conservative estimates of global Cell Free Protein Expression market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ 193.5 million in 2019. Over the next five years the Cell Free Protein Expression market will register a 6.5% CAGR in terms of revenue, the global market size will reach US$ 249.3 million by 202......
  • Global Orthokeratology Market Growth 2021-2026
    Published: 26-Jan-2021        Price: US 3660 Onwards        Pages: 134
    According to this latest study, the 2020 growth of Orthokeratology will have significant change from previous year. By the most conservative estimates of global Orthokeratology market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ 201.7 million in 2019. Over the next five years the Orthokeratology market will register a 18.1% CAGR in terms of revenue, the global market size will reach US$ 391.6 million by 2025. This report presents......
  • Global Traumatic Brain Injury Diagnostic Market Growth (Status and Outlook) 2021-2026
    Published: 26-Jan-2021        Price: US 3660 Onwards        Pages: 116
    According to this latest study, the 2020 growth of Traumatic Brain Injury Diagnostic will have significant change from previous year. By the most conservative estimates of global Traumatic Brain Injury Diagnostic market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ 47 million in 2019. Over the next five years the Traumatic Brain Injury Diagnostic market will register a 24.0% CAGR in terms of revenue, the global market size will reach US$ 110.1 m......
  • Global NK Cell Therapy Market Growth (Status and Outlook) 2021-2026
    Published: 26-Jan-2021        Price: US 3660 Onwards        Pages: 132
    According to this latest study, the 2020 growth of NK Cell Therapy will have significant change from previous year. By the most conservative estimates of global NK Cell Therapy market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ 249.2 million in 2019. Over the next five years the NK Cell Therapy market will register a 16.8% CAGR in terms of revenue, the global market size will reach US$ 463.9 million by 2025. This report presents......
  • Global Low Vision Aids Market Growth (Status and Outlook) 2021-2026
    Published: 26-Jan-2021        Price: US 3660 Onwards        Pages: 119
    According to this latest study, the 2020 growth of Low Vision Aids will have significant change from previous year. By the most conservative estimates of global Low Vision Aids market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ 420 million in 2019. Over the next five years the Low Vision Aids market will register a 6.6% CAGR in terms of revenue, the global market size will reach US$ 543.2 million by 2025. This report presents a ......
  • Global Hemostasis Valves Market Growth 2021-2026
    Published: 26-Jan-2021        Price: US 3660 Onwards        Pages: 167
    According to this latest study, the 2020 growth of Hemostasis Valves will have significant change from previous year. By the most conservative estimates of global Hemostasis Valves market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ 127.5 million in 2019. Over the next five years the Hemostasis Valves market will register a 7.5% CAGR in terms of revenue, the global market size will reach US$ 170.1 million by 2025. This report pre......
  • Global Radiotherapy Patient Positioning Devices Market Growth 2021-2026
    Published: 26-Jan-2021        Price: US 3660 Onwards        Pages: 167
    According to this latest study, the 2020 growth of Radiotherapy Patient Positioning Devices will have significant change from previous year. By the most conservative estimates of global Radiotherapy Patient Positioning Devices market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ 148.8 million in 2019. Over the next five years the Radiotherapy Patient Positioning Devices market will register a 7.9% CAGR in terms of revenue, the global market size......
  • Global Respiratory Distress Syndrome Market Growth (Status and Outlook) 2021-2026
    Published: 26-Jan-2021        Price: US 3660 Onwards        Pages: 116
    According to this latest study, the 2020 growth of Respiratory Distress Syndrome will have significant change from previous year. By the most conservative estimates of global Respiratory Distress Syndrome market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ 363.1 million in 2019. Over the next five years the Respiratory Distress Syndrome market will register a 5.7% CAGR in terms of revenue, the global market size will reach US$ 453.4 million by ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs